Table 1.
Thirteen enriched pathways by differentially expressed genes
| Pathways | Number of genes |
P-value | |
|---|---|---|---|
| Stages I–II (specific) | All stages | ||
| Cell cycle | 22↑ (9↑) | 49↑ | 1.59E–21 |
| p53 signaling pathway | 10↑ (3↑) | 27↑ | 2.66E–12 |
| ECM-receptor interaction | 4↑ (–) | 31↑ | 8.18E–13 |
| Cell communication | 6↑ (–) | 34↑ | 4.70E–04 |
| Cell adhesion molecules (CAMs) | 4↑ (2↑) | 31↑ | 5.13E–04 |
| Role of BRCA1, BRCA2 and ATR in cancer susceptibility | 4↑ (–) | 10↑ | 2.90E–03 |
| E2F1 destruction pathway | 4↑ (–) | 6↑ | 8.00E–03 |
| Wnt signaling pathway | 4↑ (–) | 17↑ | 2.22E–02 |
| Focal adhesion | 4↑ (3↑) | 41↑ | 1.32E–09 |
| 3↓ (3↓) | 4↓ | 9.81E–02* | |
| Metabolism of xenobiotics by cytochrome P450 | 4↓ (–) | 16↓ | 7.21E–04* |
| Arginine and proline metabolism | 3↓ (–) | 3↓ | 1.16E–03* |
| Fatty acid metabolism | 3↓ (–) | 7↓ | 2.56E–03* |
| Insulin signaling pathway | 5↓ (–) | 7↓ | 9.37E–04* |
Upward arrow indicates for up-regulation and downward arrow indicates down-regulation. P-value is calculated for a pathway enriched in all stages except those marked with asterisks are for early stage only.